[CAS NO. 9004-65-3] HPMC
PRODUCTS SPECIFICATIONS [9004-65-3]
DESCRIPTION [9004-65-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | C3H8O2.xCH4O.xUnspecified |
| SMILES | [R]O[C@@H]1[C@H](O[R])[C@@H](O[R])[C@H](O[C@H]2[C@H](O[R])[C@@H](O[R])[C@H](O[R])[C@@H](CO[R])O2)[C@@H](CO[R])O1.CO.CC(O)CO.[n].[x] |
2 Publications Citing Use of MCE
Summary
Hypromellose is a hydrophilic, non-ionic cellulose ether used to form swellable-soluble matrices.
In Vitro
Hypromellose provides the release of a drug in a controlled manner, effectively increasing the duration of release of a drug to prolong its therapeutic effect [1] . Hypromellose (hydroxypropylmethylcellulose) has been used in sustained-release pharmaceutical products for many years. When used in matrix tablets, these polymers hydrate on contact with water to produce a viscous gel barrier within and surrounding the tablet. The properties of hypromellose that affect the rate of drug release include the rate of diffusion of water into the dry polymer, the rate of hypromellose hydration and gel formation, the viscosity of the hydrated hypromellose and rate of hypromellose gel erosion [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Punctal occlusion using hypromellose 2% is a low-cost and safe additional treatment for dry eye. Fluorescein and rose bengal staining tests show that there was a significant reduction in signs after occlusion using hypromellose [3] . Hypromellose is effective in improving the blood glucose metabolism and suppressing oxidative stress in mice fed with a high fat diet. The antihyperglycemic and antioxidative effects of hypromellose could be partly attributed to the regulation of hepatic glucose-regulating enzyme activities and activation of the hepatic and erythrocyte antioxidant enzymes. Hypromellose may be useful as biomaterials in the development of functional food or as therapeutic agents against high fat-induced hyperglycemia and oxidative stress [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02097719 | Allergan |
Glaucoma|Ocular Hypertension
|
May 2014 | Phase 4 |
| NCT04541888 | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
Dry Eye
|
November 5, 2020 | Phase 3 |
| NCT01170884 | Allergan |
Glaucoma|Ocular Hypertension
|
December 2009 | Phase 4 |
| NCT02420834 | Aston University |
Dry Eye
|
April 2015 | Not Applicable |
| NCT00598689 | Augusta University|Novartis |
Corneal Epithelium Defect
|
October 2007 | Phase 4 |
| NCT03676335 | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
Dry Eye
|
May 9, 2018 | Phase 2 |
| NCT00909324 | Novartis Pharmaceuticals|Novartis |
Dry Eye
|
August 1, 2009 | Phase 4 |
| NCT01812044 | Duke University |
Strabismus
|
March 2013 | Not Applicable |
| NCT02382588 | Northwestern University|Bausch & Lomb Incorporated |
Herpes Zoster Keratitis
|
December 10, 2013 | Phase 2 |
| NCT05470868 | Laboratorios Sophia S.A de C.V. |
Hyperemia Eye
|
August 1, 2022 | Phase 1 |
| NCT04868175 | The University of Hong Kong |
Glaucoma|Intraocular Pressure
|
October 1, 2019 | Not Applicable |
| NCT01881126 | Allergan |
Glaucoma|Ocular Hypertension
|
June 2013 | Phase 4 |
| NCT01978015 | University of Campinas, Brazil |
Uveitis, Anterior|Cystoid Macular Edema
|
October 2011 | Phase 4 |
| NCT04020705 | Istituto di Ricerca Neuroftalmologia S.r.l.|University of Milan |
Glaucoma
|
September 22, 2015 | Not Applicable |
| NCT01525173 | Allergan |
Glaucoma|Ocular Hypertension
|
January 2012 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL (Need ultrasonic)
H 2 O : 10 mg/mL (Need ultrasonic)
-
1.
Add each solvent one by one: PBS
Solubility: 8.33 mg/mL (Infinity mM); Clear solution; Need ultrasonic and warming and heat to 60°C
References
- [1] Li CL, et al. The use of hypromellose in oral drug delivery. J Pharm Pharmacol. 2005 May;57(5):533-46.
- [2] Braund R, et al. Hypromellose films for the delivery of growth factors for wound healing.
- [3] Capita L, et al. Prospective evaluation of hypromellose 2% for punctal occlusion in patients with dry eye. Cornea. 2015 Feb;34(2):188-92.
- [4] Ban SJ, et al. Antihyperglycemic and antioxidative effects of Hydroxyethyl Methylcellulose (HEMC) and Hydroxypropyl Methylcellulose (HPMC) in mice fed with a high fat diet. Int J Mol Sci. 2012;13(3):3738-50.
Synonyms